Jazz Pharmaceuticals plc filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-05-29. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
On May 25, 2026, Anne O'Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the "Company") 2026 annual meeting of shareholders, has informed the board of directors (the "Board") that she will not stand for re-election.
Find people with the same kind of experience as the senior executive at Jazz Pharmaceuticals plc, with the record behind each one.
Find candidates like senior executive at Jazz Pharmaceuticals plcNew leaders review vendors and budgets in their first months. Get an alert the next time Jazz Pharmaceuticals plc is in the news or changes leadership.
Get an alert when Jazz Pharmaceuticals plc changes leadershipTools for this story
Each opens in a new tab, filled in for Jazz Pharmaceuticals plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.